Priority Review for Vascepa to reduce CV risk
Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted
Priority Review for Vascepa to reduce CV risk
Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted